BioDelivery Sciences International, Inc. (BDSI)
| Market Cap | 370.43M |
| Revenue (ttm) | 159.21M |
| Net Income (ttm) | 25.98M |
| Shares Out | 100.99M |
| EPS (ttm) | 0.24 |
| PE Ratio | 15.67 |
| Forward PE | 12.33 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $3.76 |
| Previous Close | $3.76 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 3.74 |
| Day's Range | 3.74 - 3.80 |
| Day's Volume | 315,963 |
| 52-Week Range | 3.04 - 5.45 |
A handful of trends might drive BioDelivery Sciences' share price growth.
BioDelivery (BDSI) delivered earnings and revenue surprises of -28.57% and 0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Sc...
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...
RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious an...
If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
BioDelivery Sciences (BDSI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.
Shares of BioDelivery Sciences Intl (NASDAQ:BDSI) rose 6.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 66.67% year over year to $0.10, which b...
On Wednesday, March 10, BioDelivery Sciences Intl (NASDAQ:BDSI) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These seven penny stocks are most likely to push through the $5 mark having built a significant head of steam in the past year. The post 7 Penny Stocks Close To Busting Through the $5 Mark appeared firs...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
RALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.
RALEIGH, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
BioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q3 2020 Results - Earnings Call Transcript
Total Company Net Revenue Increased 30% versus Prior Year Reaching a Record $39.4 Million
RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
Investors who target growth may want to consider investing in the following small-cap stocks as they represent companies whose trailing 12-month pro forma earnings per share advanced significantly on a ...
New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) New Scientific Information Further Highlights Differentiated Clinical Profile of BEL...
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
My Pound The Table Moment For BioDelivery Sciences
RALEIGH, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious ...
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.
BioDelivery Sciences International, Inc. (BDSI) Management on Q2 2020 Results - Earnings Call Transcript
BioDelivery (BDSI) delivered earnings and revenue surprises of -75.00% and 0.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious a...
BioDelivery Sciences: Fundamentals Continue Divergence From Share Price
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
RALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...
BioDelivery Sciences: Undervalued $5 Biopharma Still Growing Despite COVID-19
BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues.
BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q1 2020 Results - Earnings Call Transcript
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Keep your eyes on these two stocks in the months to come.
BioDelivery Sciences Strong As Ever But At Half The Price
About BDSI
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and... [Read more...]
| Industry Biotechnology | Founded 1997 |
| CEO Jeffrey Bailey | Employees 176 |
| Stock Exchange NASDAQ | Ticker Symbol BDSI |
Analyst Forecasts
According to 7 analysts, the average rating for BDSI stock is "Strong Buy." The 12-month stock price forecast is 6.96, which is an increase of 85.11% from the latest price.